ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,267.84
-0.74%
US Tech 100
18,150.00
-0.43%
다우존스 지수
39,065.26
-1.53%
Bitcoin
67,161.34
-1.12%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Silence Therapeutics PLC (SLN)

  7. Silence Therapeutics PLC (SLN) 뉴스

SLN

Silence Therapeutics (SLN)

Silence Therapeutics PLC
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:SLN
일자시간출처헤드라인심볼기업
2024/05/1806:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
2024/05/1703:21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
2024/05/1621:30Business WireSilence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline ProgressNASDAQ:SLNSilence Therapeutics PLC
2024/05/1505:27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SLNSilence Therapeutics PLC
2024/05/0906:14Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:SLNSilence Therapeutics PLC
2024/04/3021:30Business WireSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:SLNSilence Therapeutics PLC
2024/04/2921:30Business WireSilence Therapeutics Announces Retirement of Alistair Gray from Board of DirectorsNASDAQ:SLNSilence Therapeutics PLC
2024/04/0900:48Business WireSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
2024/03/1320:05Business WireSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
2024/03/1320:03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNASDAQ:SLNSilence Therapeutics PLC
2024/03/1320:00Business WireSilence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
2024/02/2822:00Business WireSilence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024NASDAQ:SLNSilence Therapeutics PLC
2024/02/2322:12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
2024/02/2322:00Business WireSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 TrialNASDAQ:SLNSilence Therapeutics PLC
2024/02/1423:54Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SLNSilence Therapeutics PLC
2024/02/1422:55Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SLNSilence Therapeutics PLC
2024/02/0522:00Business WireSilence Therapeutics Announces Oversubscribed $120 Million Private PlacementNASDAQ:SLNSilence Therapeutics PLC
2024/01/3121:00Business WireSilence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:SLNSilence Therapeutics PLC
2023/12/0121:00Business WireSilence Therapeutics Strengthens Executive Leadership Team with Key AppointmentsNASDAQ:SLNSilence Therapeutics PLC
2023/11/1421:00Business WireSilence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial ResultsNASDAQ:SLNSilence Therapeutics PLC
2023/11/0821:00Business WireSilence Therapeutics to Present at Jefferies London Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
2023/11/0120:00Business WireSilence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular DiseaseNASDAQ:SLNSilence Therapeutics PLC
2023/09/2620:00Business WireSilence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines ConferenceNASDAQ:SLNSilence Therapeutics PLC
2023/09/0620:00Business WireSilence Therapeutics to Participate in September Investor ConferencesNASDAQ:SLNSilence Therapeutics PLC
2023/08/3005:01Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:SLNSilence Therapeutics PLC
2023/08/1620:00Business WireSilence Therapeutics Reports Second Quarter 2023 ResultsNASDAQ:SLNSilence Therapeutics PLC
2023/08/0205:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLNSilence Therapeutics PLC
2023/07/1120:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
2023/07/1120:00Business WireSilence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma CollaborationNASDAQ:SLNSilence Therapeutics PLC
2023/05/3120:00Business WireSilence Therapeutics to Present at the Jefferies Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
 검색 관련기사 보기:NASDAQ:SLN

최근 히스토리

AMEX
SPY
SPDR S&P 500
NASDAQ
MSFT
Microsoft
FX
USDGBP
US Dollar vs Sterling
NYSE
AXP
American Express
COIN
BTCUSD
Bitcoin
AMEX
XLF
Financial Select Sector
NASDAQ
AAPL
Apple
COIN
SOLUSD
Solana
NYSE
KO
Coca Cola
NYSE
JPM
JP Morgan Chase
NASDAQ
AMZN
Amazon.com
USOTC
DTEGY
Deutsche Telekom (QX)
CCOM
US100
US Tech 100
CCOM
US500
US 500
FX
USDJPY
US Dollar vs Yen
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유